Xenotransplantation of islet cells: What can the non-human primate model bring for the evaluation of efficacy and safety?

Xenotransplantation

Volumn 22, Issue 3, 2015, Pages 231-235

  Denner, Joachim ^a   Graham, Melanie ^b  

^a ROBERT KOCH INSTITUTE   (Germany)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL WELFARE; CELL ENCAPSULATION; CLINICAL EFFECTIVENESS; DATA ANALYSIS; DECISION MAKING; DIABETES MELLITUS; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; INFECTION RISK; MEDICAL SOCIETY; NONHUMAN; NOTE; PANCREAS ISLET TRANSPLANTATION; PORCINE ENDOGENOUS RETROVIRUS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROVIRIDAE; RISK ASSESSMENT; RISK FACTOR; SAFETY; SURVIVAL RATE; THERAPY EFFECT; TRANSLATIONAL RESEARCH; VIRUS IDENTIFICATION; XENOTRANSPLANTATION; ADVERSE EFFECTS; ANIMAL; CYTOLOGY; IMMUNOLOGY; PANCREAS ISLET; PRIMATE; XENOGRAFT;

ANIMALS; HUMANS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; PRIMATES; SAFETY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84930756493     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12169     Document Type: Note

References (64)

1. Rodriguez IA, Welsh RM,. Possible role of a cell surface carbohydrate in evolution of resistance to viral infections in old world primates. J Virol 2013; 87: 8317-8326.
2. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA,. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 1988; 263: 17755-17762.
3. Kobayashi T, Cooper DK,. Anti-Gal, alpha-Gal epitopes, and xenotransplantation. Subcell Biochem 1999; 32: 229-257.
4. Cooper DK, David KC,. Clinical xenotransplantion-how close are we? Lancet 2003; 362: 557-559.
5. Kilkenny C, Parkson N, Kadyszewski E, et al., Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS ONE 2009; 4: e7824.
6. Begley CG, Ellis LM,. Drug development: raise standards for preclinical cancer research. Nature 2012; 483: 531-533.
7. Roep BO, Atkinson M, von Herrath M,. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 2004; 4: 989-997.
8. Collins FS, Tabak LA,. NIH plans to enhance reproducibility. Nature 2014; 505: 612.
9. Henderson VC, Kimmelman J, Fergusson D, et al., Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med 2013; 10: e1001489.
10. Graham ML, Bellin MD, Papas KK, et al., Species incompatibilities in the pig-to-macaque islet xenotransplant model affect transplant outcome: a comparison with allotransplantation. Xenotransplantation 2011; 18: 328-342.
11. Graham ML, Schuurman HJ,. The usefulness and limitations of the diabetic macaque model in evaluating long-term porcine islet xenograft survival. Xenotransplantation 2013; 20: 5-17.
12. Wijkstrom M, Bottino R, Cooper, DKC,. Commentary. Limitations of the pig-to-non-human primate islet transplantation model. Xenotransplantation 2013; 20: 2-4.
13. Cooper DKC, Bottino R, Satyananda V, et al., Commentary. Toward clinical islet xenotransplantation-are revisions to the IXA guidelines warranted? Xenotransplantation 2013; 20: 68-74.
14. Cardona K, Korbutt GS, Milas Z, et al., Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006; 12: 304-306.
15. Thompson P, Badell IR, Lowe M, et al., Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am J Transplant 2012; 12: 1765-1775.
16. Thompson P, Badell IR, Lowe M,. Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. Am J Transplant 2011; 11: 2593-2602.
17. Thompson P, Cardona K, Russell M, et al., CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant 2011; 11: 947-957.
18. Hering BJ, Wijkstrom M, Graham ML, et al., Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006; 12: 301-303.
19. van der Windt DJ, Bottino R, Casu A,. Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009; 9: 2716-2726.
20. Cardona K, Milas Z, Strobert E, et al., Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am J Transplant 2007; 7: 2260-2268.
21. Cooper DK, Satyananda V, Ekser B, et al., Progress in pig-to-non-human primate transplantation models (1998-2013): a comprehensive review of the literature. Xenotransplantation 2014; 21: 397-419.
22. Hering BJ, Cooper DK, Cozzi E, et al., The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-executive summary. Xenotransplantation 2009; 16: 196-202.
23. Cooper DK, Casu A,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 4: pre-clinical trial. Xenotransplantation 2009; 16: 229-238.
24. Ludwig B, Reichel A, Steffen A, et al., Transplantation of human islets without immunosuppression. Proc Natl Acad Sci USA 2013; 110: 19054-19058.
25. Hillberg AL, Kathirgamanathan K, Lam JB, et al., Improving alginate-poly-L-ornithine-alginate capsule biocompatibility through genipin crosslinking. J Biomed Mater Res B Appl Biomater 2013; 101: 258-268.
26. Jacobs-Tulleneers-thevissen D, Chintinne M, Ling Z, et al., Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia 2013; 56: 1605-1614.
27. Basta G, Montanucci P, Luca G, et al., Long-term metabolic and immunological follow-up of nonimmuno-suppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care 2011; 34: 2406-2409.
28. Tuch BE, Keogh GW, Williams LJ, et al., Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care 2009; 32: 1887-1889.
29. Gray DW,. Encapsulated islet cells: the role of direct and indirect presentation and the relevance to xenotransplantation and autoimmune recurrence. Br Med Bull 1997; 53: 777-78830.
30. Denner J, Specke V, Karlas A, et al., No transmission of porcine endogenous retroviruses (PERVs) in a long-term pig to rat xenotransplantation model and no infection of immunosuppressed rats. Ann Transplant 2008; 13: 20-31.
31. Neufeld T, Ludwig B, Barkai U, et al., The efficacy of an immunoisolating membrane system for islet xenotransplantation in minipigs. PLoS ONE 2013; 8: e70150.
32. Molano RD, Pileggi A, Berney T, et al., Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. Diabetes 2003; 52: 957-964.
33. Migliavacca B, Nano R, Antonioli B, et al., Identification of in vitro parameters predictive of graft function: a study in an animal model of islet transplantation. Transplant Proc 2004; 36: 612-613.
34. Armann B, Hanson MS, Hatch E, Steffen A, Fernandez LA,. Quantification of basal and stimulated ROS levels as predictors of islet potency and function. Am J Transplant 2007; 7: 38-47.
35. Medbury HJ, Heather J,. The cytokine and histological response in islet xenograft rejection is dependent upon species combination. Transplantation 1997; 64: 1307-1314.
36. Weber CJ, Safley S, Hagler M, Kapp J,. Evaluation of graft-host response for various tissue sources and animal models. Ann N Y Acad Sci 1999; 875: 233-254.
37. de Groot M, Schuurs TA, van Schilfgaarde R,. Causes of limited survival of microencapsulated pancreatic islet grafts. J Surg Res 2004; 121: 141-150.
38. Bottino R, Wijkstrom M, van der Windt DJ, et al., Pig-to-monkey islet xenotransplantation using multi-transgenic pigs. Am J Transplant 2014; 14: 2275-2287.
39. Casu A, Bottino R, Balamurugan AN, et al., Metabolic aspects of pig-to-monkey (Macaca fascicularis) islet transplantation: implications for translation into clinical practice. Diabetologia 2008; 51: 120-129.
40. Mueller KR, Balamurugan AN, Cline GW, et al., Differences in glucose-stimulated insulin secretion in vitro of islets from human, nonhuman primate, and porcine origin. Xenotransplantation 2013; 20: 75-81.
41. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG,. Improving bioscience research reporting: the arrive guidelines for reporting animal research. PLoS Biol 2010; 8: e1000412.
42. Fishman JA,. Infection in xenotransplantation: a clinical approach. Transplant Proc 1999; 31: 2225-2227.
43. Denner J, Tönjes RR,. Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses. Clin Microbiol Rev 2012; 25: 318-343.
44. Wilson CA, Wong S, Vanbrocklin M, et al., Extended analysis of the in vitro tropism of porcine endogenous retrovirus. J Virol 2000; 74: 49-56.
45. Denner J, Specke V, Thiesen U, et al., Genetic alterations of the long terminal repeat of an ecotropic porcine endogenous retrovirus during passage in human cells. Virology 2003; 314: 125-133.
46. Karlas A, Irgang M, Votteler J, et al., Characterisation of a human cell-adapted porcine endogenous retrovirus PERV-A/C. Ann Transplant 2010; 15: 45-54.
47. Harrison I, Takeuchi Y, Bartosch B, et al., Determinants of high titer in recombinant porcine endogenous retroviruses. J Virol 2004; 78: 13871-13879.
48. Rodrigues Costa M, Fischer N, Gulich B, et al., Comparison of porcine endogenous retroviruses infectious potential in supernatants of producer cells and in cocultures. Xenotransplantation 2014; 21: 162-173.
49. Martin U, Winkler ME, Id M, et al., Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV). Xenotransplantation 2000; 7: 138-142.
50. Denner J,. Porcine endogenous retrovirus infection of human peripheral blood mononuclear cells. Xenotransplantation 2015; 22: 151-152.
51. Blusch JH, Patience C, Takeuchi Y, et al., Infection of nonhuman primate cells by pig endogenous retrovirus. J Virol 2000; 74: 7687-7690.
52. Specke V, Tacke SJ, Boller K, et al., Porcine endogenous retroviruses: in vitro host range and attempts to establish small animal models. J Gen Virol 2001; 82: 837-844.
53. Ritzhaupt A, Vanderlaan LJ, Salomon DR, Wilson CA,. Porcine endogenous retrovirus infects but does not replicate in nonhuman primate primary cells and cell lines. J Virol 2002; 76: 11312-11320.
54. Specke V, Plesker R, Wood J, et al., No in vivo infection of triple immunosuppressed non-human primates after inoculation with high titers of porcine endogenous retroviruses. Xenotransplantation 2009; 16: 34-44.
55. Mattiuzzo G, Takeuchi Y,. Suboptimal porcine endogenous retrovirus infection in non-human primate cells: implication for preclinical xenotransplantation. PLoS ONE 2010; 5: e13203.
56. Garkavenko O, Dieckhoff B, Wynyard S, et al., Absence of transmission of potentially xenotic viruses in a prospective pig to primate islet xenotransplantation study. J Med Virol 2008; 80: 2046-2052.
57. Moscoso I, Hermida-Prieto M, Mañez R, et al., Lack of cross-species transmission of porcine endogenous retrovirus in pig-to-baboon xenotransplantation with sustained depletion of anti-alphagal antibodies. Transplantation 2005; 15: 777-782.
58. Nishitai R, Ikai I, Shiotani T, et al., Absence of PERV infection in baboons after transgenic porcine liver perfusion. J Surg Res 2005; 124: 45-51.
59. Martin U, Tacke SJ, Simon AR, et al., Absence of PERV specific humoral immune response in baboons after transplantation of porcine cells or organs. Transpl Int 2002; 15: 361-368.
60. Paradis K, Langford G, Long Z, et al., Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 1999; 285: 1236-1241.
61. Elliott RB, Escobar L, Garkavenko O, et al., No evidence of infection with porcine endogenous retrovirus in recipients of encapsulated porcine islet xenografts. Cell Transplant 2000; 9: 895-901.
62. Valdes-Gonzalez R, Dorantes LM, Bracho-Blanchet E, Rodríguez-Ventura A, White DJ,. No evidence of porcine endogenous retrovirus in patients with type 1 diabetes after long-term porcine islet xenotransplantation. J Med Virol 2010; 82: 331-334.
63. Scobie L, Padler-Karavani V, Le Bas-Bernardet S, et al., Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts. J Immunol 2013; 191: 2907-2915.
64. Wynyard S, Nathu D, Garkavenko O, et al., Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. Xenotransplantation 2014; 21: 309-323.